Return to Listing

4 result(s) for Endocrine Cancers

PI Name Protocol # Title
Kresimira Milas IRB00009420 Oregon Index of Endocrine Neoplasias (ORION)
Matthew Taylor IRB00009480 A Randomized, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
Matthew Taylor IRB00009531 A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
Matthew Taylor IRB00010987 E7080-G000-398: An Open-Label, Randomized, Multicenter, Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080

You may qualify for additional trials within our Phase 1 Program